Infectious Final

Ministry of Health of the Russian Federation

The state educational establishment of additional vocational training the St.-Petersburg     medical academy post-diploma educations

FACULTY OF INFECTIOUS DISEASES WITH THE COURSE OF LABORATORY DIAGNOSTICS AIDS

Municipal infectious diseases hospital

№ 30 named after

S.P. Botkin

Mirgorodskaya Street, 3

St-Petersburg, Russia

Phone: +7(812) 277-29-64

Fax: +7(812)277-64-96

REPORT

ABOUT USE OF THE TREATMENT-AND-PROPHYLACTIC ALIMENTARY ADDITIVE   “ENERGOLAM PLUS” AT CONVALESCENTS OF SOME INFECTIOUS DISEASES

G.I. Kirpichnikova, V.A. Neverov

INTRODUCTION

The important component of complex pathogenetic therapy of infectious diseases is use of the preparations having antioxidant and immune stimulated properties. Intensifying antioxidant protection of an organism is directed on reduction of concentration peroxide radicals, improvement of a tissue metabolism and stabilization of cellular membranes. Antioxidants, in the majority, have also immune stimulated properties.

One of such preparations is medical-alimentary biologically active additive “ENERGOLAM PLUS” with adaptogenic action. The preparation was developed and made by the company “BIO-SHELF Ltd» in capsule form, each capsule contains 50 mg of roe of the sea urchin sublimated at low temperature, 150 mg dry laminaria. The preparation represents the balanced complex of polyunsaturated fat acids, amino acids, vitamins, trace substances and alimentary fibers. Taking into account the structure of “ENERGOLAM PLUS” it is possible to say that use of the given preparation in stages treatment of acute infectious diseases can be considered as pathogenetic valid.

Clinical tests of “ENERGOLAM PLUS” in fortifying therapy of convalescents AVRI (Acute Viral Respiratory Infection) and herpetic infection caused by a virus of simple herpes of the first and second types have been carried out within the framework of the program of development of new rational scheme in stages treatments infectious patients with conditions of an immunodeficiency.

Tests were carried out in groups of ambulatories patients under observation of researchers of faculty of infectious diseases with the course of laboratory diagnostics AIDS  of the state educational establishment of additional vocational training the St.-Petersburg     medical academy post-diploma educations,  Ministry of Health of Russia.

THE PURPOSE OF RESEARCH:

Studying of an opportunity of use of the treatment-and-prophylactic alimentary additive “ENERGOLAM PLUS” in the schemes of staged therapies at convalescents of acute respiratory virus infections (ARVI) and herpetic infections caused by viruses of simple herpes of the first and second  types (VSHI).

RESEARCH PROBLEMS:

  1. Use “ENERGOLAM PLUS” in fortifying therapy of persons observed in a stage of an early convalescence from ARVI and VSHI and having attributes of an immune depression.
  2. Comparison of the received data at use “ENERGOLAM PLUS” with results of treatment in control group.

MATERIALS AND METHODS

Groups of clinical comparison There were 30 persons in observed group where each patient was convalescent of ARVI or VSHI with transmitted disease and eliminated basic displays of these infections up to 7 days before the moment of the beginning of use “ENERGOLAM PLUS”. The age of convalescents was in range 24-52 years old. There were 22 women and 8 men. 18 persons were with transmitted ARVI, symptoms of which were similar to the adenoviral and parainfluenza infections having mid-serious current.

12 persons were with transmitted VSHI, running in the form of tegmental simple herpes with localized type of lesion as gingivostomatitis and genital herpes (with frequency of relapses up to 6 times a year). All of patients by the moment of the beginning of use “ENERGOLAM PLUS” had distinctly expressed attributes of an asthenic-vegetative set of symptoms (that was one of criteria of selection) and moderately expressed residual displays of the transmitted diseases.

The observed group in 30 persons was divided into two subgroups receiving “ENERGOLAM PLUS” in different course doses in a combination with 15 convalescents were included in each subgroup in comparable allocation regarding on the age, the transmitted infections and an expressiveness of an immune depression. The control group was formed from 14 convalescents ARVI and VSHI without using any preparations during an early convalescence except polyvitaminic complex «Glutamevit».

The scheme of application of a preparation

The first group of convalescents of 15 persons has been appointed a 30-days course of reception “ENERGOLAM PLUS” in one capsule a daily dose. The second group of convalescents of 15 persons received “ENERGOLAM PLUS” in 2 capsules a daily dose a 30-days course also. The dose and course of treatment with “ENERGOLUM PLUS” have been chosen in view of references of the manufacturer.

The control of efficiency of treatment

Studying of efficiency of treatment carried out by observation over duration of conservation of a asthenic-vegetative set of symptoms and residual displays of the transmitted diseases. An estimation of efficiency of a preparation made on two basic laboratory parameters: hemocytogram and immunogram. The laboratory control was carried out up to and right after the terminations of a 30-day’s “ENERGOLAM PLUS” treatment. In control group the comparison researches were carried out in similar terms.

Statistical processing

The analysis of reliability of the received results was carried out with use of Student’s criterion.

RESULTS OF RESEARCH

Use of “ENERGOLAM PLUS” at the persons who are in a stage early convalescences of ARVI and VSHI

There is special interest of the results of use “ENERGOLAM PLUS” to therapies of the persons who are in a stage of early convalescence ARVI and VSHI, having attributes of immunodeficiency conditions (IDC). As is well known, presence of IDC is one of the main reasons of development of relapses VSHI and a lingering convalescence at ARVI. Last one is frequently accompanied by a long subfebrile condition, a lymphadenopathy, hyperplasia lymphoid follicles in a mucosa of a soft palate and a back wall of a pharynx, long cough and asthenia. At the same time relapses of VSHI and ARVI result in weighting IDC. For break of this «vicious circle» the treatment should be directed to elimination peroxide damage of lipids of cellular membranes, i.e. it is necessary to provide antioxidant protection and immune oriented therapy.

Results of clinical comparison of the basic groups and control group are submitted in Table 1.

Table1

Dynamics of some clinical signs at the surveyed persons

The analysis of results of the carried out treatment with inclusion of “ENERGOLAM PLUS” at the persons in a stage of early convalescence ARVI and VSHI and having attributes of IDC, testifies to the following. Firstly, use of “ENERGOLAM-PLUS” in stages therapies of the observed persons has yielded comparable results in two experienced groups, distinguished from results in the control group. Especially significant (statistically authentic) differences are marked between convalescents of the second group and the control group which was not receiving a preparation. Secondly, the preparation had the certain advantage in the plan of more complete and fast cupping of those clinical displays which basically are caused by the IDC. The data resulted in Table 2 more evidently testifies to the last conclusion.

Table 2

It was observed earlier disappearance of asthenic and other symptomatology at the majority of convalescents of the second group (less than in 2 weeks after start of treatment). In comparison, similar improvement was observed at convalescents from the first group only by the end of 3-rd week of treatment. Together with the clinical data in an estimation of efficiency of a preparation there were used two laboratory parameters: hemocytogram and immunogram.

At the analysis of clinical parameters of a blood there was observed an improvement of parameters hemocytogram at persons of the group 1 and, especially, the group 2 compared with the control group. The improvement was expressed in raising a level of hemoglobin and quantity of erythrocytes. In the control group these parameters changed insignificantly (see Table 3). Given positive dynamics of hematological parameters at the convalescents with treatment by “ENERGOLAM PLUS” indicates improvement of the medullar hematosis function at persons with reduced immune biological reactivity of organism.

Table 3

Studying of the immune status at surveyed persons prior to the beginning of the therapy including “ENERGOLAM PLUS”, has confirmed the presence at them mainly low-grade expressed Т-cellular (helper type) and a phagocytic immunodeficiency. The conducted treatment promoted correction of immunological parameters of convalescents of ARVI and VSHI in the Groups 1 and 2. The most distinct reaction is marked on the part of the parameters describing phagocytosis. Especially significant differences in dynamics of immunological parameters are marked between convalescents of the second group and the control group.

Table 4

Thus, both the data of clinic hematological research and parameters of the immune status testify to the advantages of application “ENERGOLAM PLUS” in comparison with use of a polyvitaminic complex in an after-care of patients of ARVI and VSHI in the period of an early convalescence.

CONCLUSION

Results of the carried out research testify to therapeutic efficiency of “ENERGOLAM PLUS” with two capsules in a daily dose with a course of 30 days in stages therapies of the persons in a stage of early convalescence of ARVI and VSHI and having attributes of an immune depression. It is necessary to note a good acceptability of this preparation and absence of side-effects. At the comparative analysis of the received data there was confirmed that using it in a complex with Polyvitaminums “ENERGOLAM PLUS” results in improvement of the general status of an organism, reduction of duration characteristic for these sick clinical signs of disease. Some hematological and immunological parameters are essentially improved, in particular describing phagocytosis. Thus, “ENERGOLAM PLUS” can be recommended to application in treatment of the persons who are in a stage of early convalescence of ARVI and VSHI.

On December 10, 2003

Понравилась статья? Поделиться с друзьями:
Энерголам плюс
Добавить комментарий

;-) :| :x :twisted: :smile: :shock: :sad: :roll: :razz: :oops: :o :mrgreen: :lol: :idea: :grin: :evil: :cry: :cool: :arrow: :???: :?: :!: